Loading page…

Vasundhara Rasayans Ltd (VRL) · mywealthgrid

About

Vasundhara Rasayans Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹46 Cr

P/E

10.9×

P/B

1.1×

Dividend yield

2.8%

ROE

15.1%

ROCE

21.5%

Debt / equity

0.04

OPM

16.2%

EPS (TTM)

₹13.3

Book value

₹128.6

52-week high

₹213.2

52-week low

₹105.7

₹144.4-21.1%1Y

Beta

0.94

Moves with the index

Volatility (1y)

50.6%

Annualised, daily returns

RSI (14)

48.9

Neither overbought nor oversold

Rel. strength (1y)

-31.9%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+High return on capital employed of 22.2%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 20.7×
+Dividend yield of 2.8%
+Dividend payout of 30.3% of profit
+High promoter holding of 62% with no pledge

Cons

No red flags triggered.

Research score

Structured signal from quality, growth, valuation and momentum.

42/100

Business quality: 66
Growth: 1
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	17	20	21	21	27	38	37	34	36
COGS	-8	-9	-9	9	14	18	16	15	15
Gross profit	—	—	—	12	13	20	21	19	21
	23	28	28	9	11	14	14	14	15
	2	1	3	3	2	6	6	4	6
OPM %	10.8%	6.1%	13.3%	13.2%	8%	14.5%	17.3%	11.9%	16.2%
Depreciation	0	0	0	0	0	0	0	0	0
Interest	0	0	0	0	0	0	0	0	0
	8	1	1	1	1	2	2	2	3
Profit before tax	9	2	4	4	3	7	8	6	8
Tax	—	—	1	1	1	2	2	2	2
Tax %	—	—	27.6%	23.5%	28.5%	25.1%	25.8%	26.3%	26.3%
	7	2	3	3	2	6	6	4	6
PAT margin %	39.3%	8%	13.9%	14.1%	8.1%	14.7%	15.8%	12.5%	16.2%
EPS (₹)	20.5	5.9	9.3	9.4	6.8	17.6	18.4	13.4	18.2
EPS adjusted (₹)	—	—	—	9.4	6.8	17.6	18.4	13.4	18.2
	0%	16.9%	16.1%	16%	14.6%	11.4%	10.8%	14.9%	11%
Annual report	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	3	3	3	3	3	3
Reserves	—	18	24	29	32	38
	—	1	4	2	4	2
	—	3	4	3	3	5
Total equity & liabilities	—	26	35	37	43	48
	1	1	1	2	2	2
CWIP	—	0	0	0	0	0
Investments	—	0	0	1	2	3
	1	24	34	34	38	43
Total assets	1	26	35	37	43	48

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	8	-7	6	-6	-2
	1	1	-1	0	2
	1	2	-3	1	-3
Net cash flow	10	-3	2	-4	-3
Free cash flow	8	-7	4	-6	-2
CFO / Operating profit %	367.4%	-118%	94.4%	-144%	-27.3%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	56.4%	47.9%	51.6%	56.1%	54.5%	57.7%
EBITDA margin %	6.1%	13.3%	13.2%	8%	14.5%	17.3%	11.9%	16.2%
EBIT margin %	5.8%	13.1%	13.1%	7.6%	14.2%	16.8%	10.9%	15%
PAT margin %	8%	13.9%	14.1%	8.1%	14.7%	15.8%	12.5%	16.2%
Working capital
Receivable days	—	—	—	100	77	61	45	76
Inventory days	—	—	—	58	79	39	44	37
Payable days	—	—	—	58	49	40	43	68
NWC days	—	—	—	100	108	60	46	45
Leverage
Current ratio	—	—	—	6.2	4.37	7.76	5.15	6.87
Debt to EBITDA	—	—	—	0.61	0.73	0.31	1.04	0.31
Debt to equity	—	—	—	0.06	0.15	0.06	0.12	0.04
Interest coverage	74.3	137.3	131	77	38.4	31.4	22.4	20.7
Asset turnover	—	—	15.53	1.05	1.1	0.99	0.79	0.75
Return ratios
Return on assets %	—	—	218.2%	8.5%	16.2%	15.7%	9.9%	12.1%
Return on capital employed %	—	—	—	14.3%	31.7%	27.4%	17.6%	21.5%
Return on equity %	—	—	—	10.1%	20.8%	18.3%	12%	14.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	61.98%	61.98%	61.98%	61.98%	61.98%	61.98%	61.98%	61.98%	61.98%	61.98%	61.98%	61.98%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	38.02%	38.02%	38.02%	38.02%	38.02%	38.02%	38.02%	38.02%	38.02%	38.02%	38.02%	38.02%
No. of shareholders	—	—	—	—	—	—	—	—	6,237	6,080	6,006	5,977

Promoter holding up 0 percentage points since Sep 2023.

9 deals · 10 Aug 2021 – 21 Aug 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
21 Aug 2024	MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED	Bulk	BSE	Buy	15,947	₹304.70	₹0.49 Cr
29 May 2024	SUMANCHEPURI	Bulk	BSE	Sell	17,096	₹244.05	₹0.42 Cr
29 May 2024	AMRITA JAIN	Bulk	BSE	Sell	16,592	₹243.52	₹0.40 Cr
29 May 2024	AMRITA JAIN	Bulk	BSE	Buy	16,592	₹242.38	₹0.40 Cr
16 Nov 2022	KETAKI PRIYADARSHAN SIRAS	Bulk	BSE	Buy	17,920	₹142.25	₹0.25 Cr
15 Nov 2022	VIJAYKUMAR .	Bulk	BSE	Sell	28,364	₹132.53	₹0.38 Cr
15 Nov 2022	VIJAYKUMAR .	Bulk	BSE	Buy	3,000	₹137.75	₹0.04 Cr
20 Sept 2021	PRADEEP KUMAR JAIN	Bulk	BSE	Sell	20,310	₹166.87	₹0.34 Cr
10 Aug 2021	PCS SECURITIES LIMITED	Bulk	BSE	Buy	20,000	₹135.48	₹0.27 Cr

1–9 of 9

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. RAJESH POKERNAExecutive Director-MD
Mr. SUNIL JAIN KUMARExecutive Director
Mr. SANJAY KUMAR JAINExecutive Director
Mrs. SEEMA JAINExecutive Director
Mr. MANISH KUMAR JAINExecutive Director
Mr. MANISH JAINNon-Executive - Independent Director
Mr. VINOD KUMAR JAINNon-Executive - Independent Director
Mr. ASHOK KUMAR JAINNon-Executive - Independent Director
Mr. KODAKANDLA SIDARSANAMNon-Executive - Independent Director
Mr. RAVI JAINNon-Executive - Independent Director
Mr. Santosh Kumar JhaWhole Time Company Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Vasundhara Rasayans Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

8

Final dividend18 Aug 2026 · ex-date₹2
Final dividend19 Sept 2025 · ex-date₹2
Final dividend23 Sept 2024 · ex-date₹2
Final dividend22 Aug 2023 · ex-date₹2
Final dividend23 Sept 2022 · ex-date₹1
Dividend dividend22 Sept 2021 · ex-date₹1.5
Dividend dividend18 Dec 2020 · ex-date₹1.5
Dividend dividend3 Oct 2019 · ex-date₹1

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

13 announcementsExport CSV

30 Sept 2026, 4:20 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

27 Aug 2026, 3:50 pmAGM/EGM

Vasundhara Rasayans Ltd - 538634 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

Postal Ballot PDF

25 Aug 2026, 3:58 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

16 Aug 2026, 1:52 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

14 Aug 2026, 4:29 pmResult

Financial Results For The Quarter Ended 30.06.2026

Financial Results PDF

14 Aug 2026, 4:03 pmBoard Meeting

Board Meeting Outcome for Outcome Of The Board Meeting Held On 14.08.2026

Outcome of Board Meeting PDF

1 Aug 2026, 5:14 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

1 Aug 2026, 5:06 pmAGM/EGM

Notice Of 39Th Annual General Meeting Scheduled To Be Held On Tuesday, 25Th August, 2026

AGM PDF

Date	Category	Subject	Filing
30 Sept 2026, 4:20 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
27 Aug 2026, 3:50 pm	AGM/EGM Postal Ballot	Vasundhara Rasayans Ltd - 538634 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

Loading announcements…

Vasundhara Rasayans Ltd

Vasundhara Rasayans Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

8

1

Announcements

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

8

1

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Vasundhara Rasayans Ltd

Vasundhara Rasayans Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends8

Board meetings1

Announcements

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Dividends8

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

8

1

8

1